和黃醫藥(00013)與信達生物宣佈呋喹替尼 (fruquintinib) 聯合信迪利單抗 (sintilimab)用於治療晚期子宮內膜癌的中國新藥上市申請獲受理並獲納入優先審評

Post Content

Read More 

You may also like...

Generated by Feedzy